Sildenafil (Generic) Pharmacokinetics: Absorption, Distribution, Metabolism, and Excretion

What Is Sildenafil and How Does It Work?

Sildenafil is a selective phosphodiesterase type 5 (PDE5) inhibitor that amplifies cyclic guanosine monophosphate (cGMP) signaling in smooth muscle cells. The landmark Goldstein et al. Trial published in the New England Journal of Medicine (1998, N=532) established that oral sildenafil at doses of 25 to 100 mg produced erections sufficient for intercourse in 69% of men with erectile dysfunction versus 22% on placebo [1]. That mechanistic foundation remains the reference point for all subsequent pharmacokinetic-pharmacodynamic modeling.

Mechanism at the Molecular Level

When sexual stimulation triggers nitric oxide (NO) release from penile endothelium and nerve terminals, NO activates soluble guanylyl cyclase, raising intracellular cGMP. Elevated cGMP relaxes corporal smooth muscle by activating protein kinase G, which phosphorylates myosin light-chain phosphatase and reduces intracellular calcium. PDE5 ordinarily degrades cGMP, curtailing this response. Sildenafil binds competitively to the catalytic domain of PDE5 with an inhibitory constant (Ki) of approximately 3.9 nM, as characterized in radioligand binding studies [2]. The drug is roughly 1,000-fold more selective for PDE5 than for PDE3 (the cardiac isoform), which underpins its relative cardiovascular safety at therapeutic doses.

Selectivity Across PDE Isoforms

Selectivity matters clinically. Sildenafil inhibits PDE6 (retinal) at roughly 10-fold higher concentrations than PDE5, explaining transient color-vision disturbances reported by approximately 3% of subjects in dose-ranging trials [1]. Its selectivity over PDE1, PDE2, and PDE4 exceeds 4,000-fold, limiting off-target bronchial and cardiac effects at standard doses [2].

Absorption: How Quickly Does Sildenafil Enter Systemic Circulation?

Sildenafil is well absorbed from the gastrointestinal tract after oral administration. Absolute bioavailability averages 41% (range 25 to 63%) due to first-pass hepatic extraction [3]. Peak plasma concentration (Cmax) occurs 30 to 120 minutes post-dose under fasted conditions, making the 30 to 60-minute pre-sexual-activity dosing window clinically rational.

Effect of Food on Absorption

A high-fat meal delays Tmax by approximately 60 minutes and reduces Cmax by about 29% without meaningfully changing overall exposure (AUC) [3]. The FDA-approved prescribing information for sildenafil tablets therefore notes that patients seeking the fastest onset should take the drug on an empty stomach. Grapefruit juice inhibits intestinal CYP3A4 and can increase sildenafil AUC by up to 23%, a modest but real interaction [4].

Dose Proportionality

Pharmacokinetic studies across the 25 to 100 mg dose range show that Cmax and AUC increase in an approximately dose-proportional manner [3]. At 100 mg, mean Cmax is roughly 560 ng/mL under fasted conditions. Sildenafil 20 mg, the approved pulmonary arterial hypertension (PAH) dose given three times daily, produces steady-state AUC values that are substantially lower and do not cause the same peak-exposure profile seen with the 100 mg ED dose.

Distribution: Where Does Sildenafil Go in the Body?

The mean steady-state volume of distribution is approximately 105 liters, indicating extensive tissue penetration beyond plasma [3]. Sildenafil is approximately 96% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein, leaving a small unbound fraction to drive pharmacological activity [3].

Blood-Brain Barrier and Compartmental Penetration

Because of high protein binding and the drug's physicochemical properties, CNS penetration is low. Sildenafil does not accumulate meaningfully in the central nervous system at therapeutic doses, which is consistent with the absence of cognitive side effects in clinical trials [2]. Pulmonary vascular smooth muscle, however, concentrates the drug via PDE5-rich tissue binding, a property that supports its use in pulmonary arterial hypertension at doses as low as 20 mg three times daily [5].

Drug Transfer to Semen

Sildenafil is detectable in semen after oral dosing. A pharmacokinetic study found semen concentrations roughly 0.001% of peak plasma concentrations, a level considered clinically irrelevant for female partners [2].

Metabolism: CYP3A4, CYP2C9, and the Active Metabolite

Sildenafil undergoes extensive hepatic metabolism. CYP3A4 is the principal enzyme responsible, with CYP2C9 contributing a secondary pathway [3]. The dominant metabolite is N-desmethylsildenafil (UK-103,320), formed by N-demethylation of the piperazine ring.

N-Desmethylsildenafil: The Active Metabolite

N-desmethylsildenafil retains approximately 50% of the PDE5 inhibitory potency of the parent compound [3]. At standard oral doses, plasma concentrations of this metabolite reach approximately 40% of parent drug concentrations, contributing meaningfully to the overall pharmacological effect. Its half-life mirrors that of the parent drug at roughly 4 hours, so the metabolite does not accumulate disproportionately with single-dose use.

CYP3A4 Drug Interactions: The Highest-Risk Category

Strong CYP3A4 inhibitors (ritonavir, ketoconazole, itraconazole, clarithromycin) can increase sildenafil AUC by two-fold to eleven-fold. Co-administration of ritonavir 500 mg twice daily with sildenafil 100 mg raised sildenafil AUC by 11-fold and Cmax by 4-fold in a dedicated interaction study [4]. The FDA label consequently contraindicates sildenafil use with ritonavir in the ED indication at doses above 25 mg per 48 hours [3]. Strong CYP3A4 inducers (rifampin) reduce AUC by approximately 57% [4].

CYP2C9 Interactions

CYP2C9 inhibitors such as fluconazole can modestly raise sildenafil exposure, though the magnitude is smaller than CYP3A4-mediated interactions. This pathway becomes more clinically relevant in patients who are CYP3A4 poor metabolizers [2].

Excretion: Half-Life, Routes, and Duration of Action

The terminal elimination half-life of sildenafil is approximately 3.7 to 4.5 hours in healthy adult men [3]. This half-life governs the 4 to 6-hour clinical window of effect. After a single oral dose, approximately 80% of the administered dose is recovered in feces (as metabolites) and approximately 13% in urine [3]. Less than 0.001% of the dose is excreted unchanged in urine, confirming that renal clearance of unmetabolized drug is negligible.

Hepatic Impairment Effects

Mild to moderate hepatic impairment (Child-Pugh A and B) increases sildenafil AUC by approximately 84% compared with matched controls without liver disease [3]. The FDA label advises starting at 25 mg in patients with hepatic impairment and titrating cautiously. Severe hepatic impairment (Child-Pugh C) is listed as a contraindication in most prescribing contexts due to the expected further increase in exposure.

Renal Impairment Effects

Severe renal impairment (creatinine clearance <30 mL/min) increases sildenafil AUC by approximately 100% [3]. The proposed mechanism is reduced renal clearance of the N-desmethyl metabolite rather than altered hepatic metabolism. Dose adjustment to 25 mg is recommended in this population. Patients on hemodialysis show similar AUC increases to those with severe CKD, since sildenafil and its metabolite are not readily dialyzable due to high protein binding [4].

Age and Sex Effects

In men older than 65 years, sildenafil AUC is approximately 40% higher than in younger adult men (18 to 45 years), attributed to reduced hepatic first-pass extraction [3]. The FDA label for ED recommends starting at 25 mg in men over 65. Published pharmacokinetic data in women derive primarily from PAH studies. Sildenafil clearance in women is approximately 37% lower than in weight-matched men, yielding higher AUC at identical doses [5]. This difference has clinical implications for dosing in female PAH patients.

Pharmacokinetic-Pharmacodynamic Relationship

Understanding exposure-response relationships helps explain why the same 100 mg dose produces dramatically different outcomes across patients. A population pharmacokinetic analysis using data from the key ED trials found that the probability of achieving an erection sufficient for intercourse increased in a sigmoidal Emax relationship with free sildenafil plasma concentration [2]. Patients with lower baseline NO bioavailability (diabetic neuropathy, radical prostatectomy) require higher plasma exposures to achieve equivalent responses, explaining why 25 mg is adequate for some men while others need 100 mg.

Onset and Duration in Clinical Practice

Clinically detectable PDE5 inhibition occurs within 30 minutes of a fasted 50 mg dose in most pharmacodynamic studies [1]. Peak pharmacodynamic effect tracks Tmax at 60 to 90 minutes. The 4 to 6-hour window of enhanced erectile response corresponds to plasma concentrations above the half-maximal effective concentration (EC50) for PDE5 inhibition. By 8 hours post-dose, plasma concentrations fall below this threshold for the majority of patients, which is why the label advises dosing no more than once per 24-hour period.

Nitrate Interaction: The Pharmacodynamic Risk

Sildenafil's mechanism directly amplifies NO-cGMP signaling. Co-administration with any form of organic nitrate (nitroglycerin, isosorbide mononitrate, amyl nitrite) produces additive vasodilation and can cause severe, potentially fatal hypotension [3]. This interaction is absolute and dose-independent. The American Heart Association and American College of Cardiology guidelines specify that sildenafil is contraindicated within 24 hours of short-acting nitrate use [6].

Steady-State Pharmacokinetics at the 20 mg PAH Dose

Sildenafil 20 mg three times daily (the Revatio indication for PAH) reaches steady state within 1 to 2 days [5]. At steady state, the accumulation ratio for AUC is approximately 1.5-fold compared with single-dose, reflecting the 8-hour dosing interval relative to the 4-hour half-life. The SUPER-1 trial (N=278) demonstrated that sildenafil 20, 40, and 80 mg three times daily all improved 6-minute walk distance from baseline in PAH patients, with the 20 mg dose achieving 45-meter improvement versus placebo at 12 weeks (P<0.001) [5]. The pharmacokinetic basis for the three-times-daily regimen is the need to maintain plasma concentrations above the EC50 for pulmonary vascular PDE5 throughout the dosing interval.

Special Populations: Practical Dosing Implications

Pediatric Use

The FDA has not approved sildenafil for pediatric pulmonary arterial hypertension, and a 2012 FDA safety communication warned against use in children aged 1 to 17 years following data from the STARTS-2 long-term extension showing higher mortality at high doses [7]. Pharmacokinetic modeling in pediatric PAH patients showed non-linear weight-based dosing requirements, with younger children requiring proportionally higher weight-adjusted doses to achieve target adult exposures.

Drug-Drug Interactions Summary

Alpha-blockers (tamsulosin, doxazosin) combined with sildenafil can cause additive hypotension because both lower systemic vascular resistance by independent pathways [3]. This interaction is particularly pronounced within 4 hours of alpha-blocker dosing. The FDA recommends a 4-hour separation and initiating sildenafil at 25 mg when alpha-blockers are part of the regimen.

Amlodipine co-administration reduces sildenafil Cmax by approximately 6% with no meaningful change in AUC, a clinically negligible interaction [4]. Most calcium channel blockers are unlikely to require dose adjustment.

Bioequivalence Standards for Generic Sildenafil

Generic formulations of sildenafil must demonstrate bioequivalence to the reference listed drug (Viagra or Revatio) under FDA 21 CFR Part 320 standards. Bioequivalence requires that the 90% confidence intervals for the geometric mean ratio of AUC and Cmax fall within 80 to 125% of the reference product [8]. As of 2017, multiple generic sildenafil citrate products achieved FDA approval following dissolution testing and in vivo bioequivalence studies in healthy volunteers. Patients can expect pharmacokinetically equivalent performance from any FDA-approved generic, though excipient differences may theoretically affect dissolution rate in some formulations.

The FDA Orange Book lists over 30 approved generic sildenafil citrate tablet entries across 20 mg, 25 mg, 50 mg, and 100 mg strengths [8]. All reference the same absorption, distribution, metabolism, and excretion profile described in this article, since the active moiety and its pharmacokinetic behavior are determined by the molecule, not the manufacturer.